An Open Label, Non-Randomized, Multi-Center Study To Assess The Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra-Discally in Patients With Degenerative Disc Disease
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Adipose-derived autologous stem cell therapy Bioheart (Primary)
- Indications Intervertebral disc degeneration
- Focus Therapeutic Use
- Sponsors U.S. Stem Cell
- 15 Mar 2017 Status changed from recruiting to completed.
- 28 Apr 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
- 04 Apr 2014 New source identified and integrated (ClinicalTrials.gov record; NCT02097862)